Discordance between patient and physician global assessment scores is common in SSc, with each incorporating different factors when assessing.

The FDA has granted Fast Track designation to BM-3103, a novel topical mTOR inhibitor for epidermolysis bullosa simplex currently in phase 2.

Topical corticosteroids for the treatment of dermatologic conditions are not associated with an increased risk for incident type 2 diabetes.

Treatment patterns and patient characteristics varied among those with vitiligo based on the proportion of BSA involved and across age groups.

Nearly one-third of patients with NSCC have koilocytosis on histopathology, which is indicative of having HPV-positive status ...

Misinformation about sunscreen on TikTok receives higher levels of engagement than correct information, researchers report.

Rextovy is supplied in a carton containing 2 intranasal devices, with each unit containing a single spray of naloxone HCl 4mg. The Food and Drug Administration (FDA) has approved Rextovy ™ (naloxone ...

A non-prescription continuous glucose monitor has been cleared for use in pediatric patients aged 2 years and older with diabetes who do not use insulin. HealthDay News — The U.S. Food and Drug ...

An insulin inhalation powder has been approved by the FDA for pediatric patients with type 1 or type 2 diabetes.

The real-world use of CAL/BDP PAD-cream was associated with improvement across multiple clinician- and patient-reported outcomes.